Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.

Zhe RuanYonglan TangTing GaoChunhong LiRongjing GuoChao SunXiaoxi HuangZhuyi LiTing Chang

Published in: CNS neuroscience & therapeutics (2024)

Tocilizumab is safe and effective in improving the MG-ADL score and reducing prednisone dose in refractory AChR-Ab+ gMG, suggesting tocilizumab has the potential to be a valuable therapeutic option for such patients.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
myasthenia gravis
end stage renal disease
rheumatoid arthritis patients
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
disease activity
climate change